Progyny (NASDAQ:PGNY) Issues FY 2026 Earnings Guidance

Key Points

• Progyny raised its FY 2026 outlook, forecasting EPS of $2.04–$2.10 versus the $1.86 analyst consensus, while maintaining revenue guidance at approximately $1.4 billion. Q3 2026 EPS guidance was set at $0.50–$0.52.
• The company recently reported quarterly EPS of $0.55, well above the $0.33 consensus estimate, on revenue of $350.51 million. Its board also authorized a $200 million share-repurchase program, covering up to 10.3% of outstanding shares.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $33.25, compared with the stock’s recent price of $30.21. Progyny shares have traded between $16.10 and $33.06 over the past year.

Progyny (NASDAQ:PGNY - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.040-2.100 for the period, compared to the consensus earnings per share estimate of 1.860. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q3 2026 guidance to 0.500-0.520 EPS.

Wall Street Analyst Weigh In

Several brokerages have commented on PGNY. Zacks Research upgraded Progyny from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, July 8th. Bank of America boosted their target price on Progyny from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, June 2nd. Truist Financial increased their target price on shares of Progyny from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Monday, June 22nd. Barclays restated an "equal weight" rating and issued a $34.00 price target (up from $27.00) on shares of Progyny in a report on Tuesday, July 28th. Finally, Citizens Jmp lifted their price target on shares of Progyny from $30.00 to $31.00 and gave the company a "market outperform" rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $33.25.

Progyny Price Performance

NASDAQ PGNY traded down $1.16 during trading hours on Thursday, hitting $30.21. The company had a trading volume of 1,863,949 shares, compared to its average volume of 1,465,451. The firm's 50 day moving average is $28.93 and its 200 day moving average is $23.36. Progyny has a fifty-two week low of $16.10 and a fifty-two week high of $33.06. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 39.23, a P/E/G ratio of 2.50 and a beta of 1.01.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company had revenue of $350.51 million for the quarter, compared to analysts' expectations of $348.63 million. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities analysts anticipate that Progyny will post 1.19 EPS for the current year.

Progyny announced that its Board of Directors has approved a stock repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its stock is undervalued.

Insider Activity

In other Progyny news, Director Cheryl Scott sold 7,439 shares of the company's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $26.39, for a total value of $196,315.21. Following the completion of the transaction, the director owned 19,772 shares in the company, valued at $521,783.08. This represents a 27.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Geoffrey Clapp sold 1,530 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider directly owned 59,117 shares of the company's stock, valued at $1,512,212.86. This trade represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,916 shares of company stock worth $939,875 in the last ninety days. 9.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Progyny

A number of large investors have recently added to or reduced their stakes in PGNY. Invesco Ltd. lifted its holdings in Progyny by 17.2% in the 4th quarter. Invesco Ltd. now owns 466,769 shares of the company's stock worth $11,987,000 after buying an additional 68,473 shares in the last quarter. Caitlin John LLC boosted its position in Progyny by 72.3% in the 4th quarter. Caitlin John LLC now owns 12,796 shares of the company's stock valued at $329,000 after buying an additional 5,371 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Progyny during the fourth quarter valued at about $275,000. XTX Topco Ltd acquired a new stake in shares of Progyny during the fourth quarter valued at about $3,058,000. Finally, VARCOV Co. purchased a new stake in shares of Progyny during the fourth quarter worth about $491,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source